Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.58 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.52 |
| ▸ | MAT2A | P31153 | 4/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15454733 | 0.88 | ROCK2 (0.50) | ROCK2AAK1MAT2AIDO1CYP11B1 | |
| SCHEMBL15562342 | 0.87 | ROCK2 (0.49) | ROCK2AAK1MAT2AIDO1CYP11B1 | |
| SCHEMBL15562341 | 0.86 | ROCK2 (0.48) | ROCK2AAK1MAT2AIDO1CYP11B1 | |
| SCHEMBL20181498 | 0.82 | ROCK2 (0.43) | ROCK2AAK1MAT2ACHUKGABRA1 | |
| SCHEMBL19946167 | 0.80 | AAK1 (0.54) | ROCK2AAK1GABRA1GABRA5 | |
| SCHEMBL16347500 | 0.79 | ROCK2 (0.58) | ROCK2AAK1 | |
| SCHEMBL19946180 | 0.78 | AAK1 (0.52) | ROCK2AAK1MAT2AGABRA1GABRG2 | |
| SCHEMBL19946166 | 0.77 | GABRA1 (0.41) | ROCK2AAK1MAT2AGABRA1GABRG2 | |
| SCHEMBL16347523 | 0.76 | ROCK2 (0.61) | ROCK2AAK1CYP11B1CYP11B2 | |
| SCHEMBL19946112 | 0.74 | AAK1 (0.56) | ROCK2AAK1MAT2AGABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292124-B1 | 6H-ISOCHROMENO[3,4-C]PYRIDINES AND BENZO[C][1,7]NAPHTHYRIDIN-6-(5H)-ONES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-3292124-B1 | 6H-ISOCHROMENO[3,4-C]PYRIDINES AND BENZO[C][1,7]NAPHTHYRIDIN-6-(5H)-ONES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10174044-B2 | Fused pyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174044-B2 | Fused pyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| EP-3292124-A2 | FUSED PYRIDINES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174044-B2 | Fused pyridines as kinase inhibitors | AAK1, NCK1, ADCK1 | ROCK2 966/4885AAK1 1/4885MAT2A 2897/4885 |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | AAK1, NCK1, ADCK1 | ROCK2 966/4885AAK1 1/4885MAT2A 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.